SCHEMBL26051105

SCHEMBL26051105

Cc1ccc2[nH]c(-c3nccc(C)c3CO)nc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CBFB Q13951 6/20 0.40
▸ METAP2 P50579 3/20 0.39
▸ METAP1 P53582 3/20 0.39
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ PKM P14618 1/20 0.38
▸ MAP2K4 P45985 2/20 0.36
▸ MAPT P10636 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ RUNX1 Q01196 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ RECQL P46063 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19228809 0.85 CBFB (0.49) CBFBMETAP2METAP1NPC1RAB9A
SCHEMBL19228812 0.80 RUNX1 (0.56) CBFBMETAP2METAP1NPC1RAB9A
SCHEMBL125119 0.77 CBFB (0.49) CBFBMETAP2METAP1NPC1RAB9A
SCHEMBL26051103 0.75 CBFB (0.41) CBFBMETAP2METAP1NPC1RAB9A
SCHEMBL1171203 0.73 NPC1 (0.51) CBFBMETAP2METAP1NPC1RAB9A
SCHEMBL19228826 0.73 ALOX5 (0.46) CBFBMETAP2METAP1NPC1RAB9A
SCHEMBL32680229 0.72 CBFB (0.47) CBFBMETAP2METAP1NPC1RAB9A
SCHEMBL124418 0.72 CBFB (0.54) CBFBMETAP2METAP1NPC1RAB9A
SCHEMBL125202 0.72 CBFB (0.59) CBFBMETAP2METAP1NPC1RAB9A
SCHEMBL19228816 0.71 CBFB (0.45) CBFBNPC1RAB9APKMMAP2K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230277454-A1 NANO-EMULSION OF CBFß-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVER MASSACHUSETTS EYE AND EAR INFIRMARY 2023-09-07 — — US disclosed
US-11739326-B2 RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2023-08-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11739326-B2 RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition RUNX1, CXCL12, MITF CBFB 7/4885METAP2 4202/4885METAP1 3750/4885
US-20230277454-A1 NANO-EMULSION OF CBFß-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVER RUNX1, CBFB, IKZF1 CBFB 2/4885METAP2 4830/4885METAP1 4694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback